Compass Builds a Commercial Case for COMP360

NEW YORK – Compass Pathways is advancing COMP360, its proprietary synthetic psilocybin for treatment-resistant depression (TRD), through a rolling FDA New Drug Application, with a commercial launch targeted for H1 2027. Alongside the regulatory push, the company has begun laying out the practical architecture of how COMP360 will be sold, administered, billed, and accessed – approaches that will shape the drug’s market entry as much as any clinical result.

The most telling element of Compass’ go-to-market thinking is how deliberately it relies on infrastructure already built by Johnson & Johnson’s Spravato (esketamine). Spravato, approved for TRD in 2019, requires supervised office-based administration and has grown to over $1.7 billion in annual sales. Chief Commercial Officer Lori Englebert has publicly stated that a Spravato-equipped room is a near-ready COMP360 site – the shared logistical requirements are substantial:

• supervised multi-hour sessions,
• multidisciplinary care teams, and
• existing REMS familiarity.

More than 8,000 U.S. centers already offer multi-hour treatments, and Compass expects COMP360 to fit seamlessly across those settings upon approval.

Compass is planning a buy-and-bill model, where clinics purchase COMP360 directly and bill insurance payers afterward, an approach with which about 30% to 40% of Spravato volume already operates. The company is also pursuing a J-code, a billing designation designed to ease provider-side reimbursement. CPT codes related to psychedelic administration went into effect in January 2024, confirmed by the American Medical Association. Chief Patient Officer Steve Levine has noted that hour-by-hour billing for a roughly six-hour COMP360 session could compare favorably with current Spravato clinic economics.

Compass has not published a list price. Englebert has been direct about the reason. The company is waiting for 26-week durability data from its second Phase 3 study before committing to a figure, because dosing frequency is expected to drive pricing directly.

Moreover, no commercial transaction can occur until the DEA reschedules COMP360 from Schedule I. Under statute, the DEA has 90 days following FDA approval to act. A White House Executive Order directs the DEA to initiate and complete rescheduling review for psychedelic treatments that have successfully completed Phase 3 trials, so that rescheduling can proceed as quickly as possible. Compass is actively coordinating with the agency to streamline that process. The company reports that approximately 90% of the U.S. population lives in states that intend to reschedule COMP360 within 30 days of federal DEA action.

No classic psychedelic has ever navigated an FDA approval and the distribution infrastructure that follows it. Compass’ commercial approach [methodical, anchored to an existing treatment channel, and measured on pricing] reflects the stakes of getting it right the first time. Payer coverage decisions remain open. The DEA timeline, for all the executive-level urgency, is not yet settled.

The drug’s clinical profile is increasingly well-established. The commercial proof of concept is still ahead, and in a sector that has spent years waiting for its first FDA-approved classic psychedelic, 2027 may be when the story shifts from clinical to commercial.